NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
A Global, Phase 3, Multicenter, Open-Label Study to Assess the Long-Term Safety and Tolerability of NBI-1117568 in Adults With Schizophrenia
- Schizophrenia
At a glance
- Phase
- Phase 3
- Study type
- Interventional
- Sponsor
- Neurocrine Biosciences
- Enrolment target
- 600
- Started
- 11 July 2025
- Main results due
- December 2031
- Study sites
- 61
- Registry updated
- 25 September 2026
Can you take part?
- Ages 18 years to 65 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Key Inclusion Criteria: * Participant has a primary diagnosis of schizophrenia * Participants taking prohibited medications, including antipsychotics, must discontinue before study participation * Participant must reside in a stable housing situation Key Exclusion Criteria: * Participant has known hypersensitivity to any component of the formulation of NBI-1117568 * Participant has an unstable or poorly controlled medical condition or chronic disease * Participant is considered by the investigator to be at imminent risk of suicide or injury to self or others * Participant has a diagnosis of moderate or severe substance use disorder (with the exception of nicotine or caffeine dependence) within 6 months prior to screening * Participant has a positive alcohol test or drug screen for disallowed substances * Participant has a history of poor or suspected poor compliance in clinical research studies and/or in the investigator's opinion, the participant is not capable of adhering to the protocol requirements. Note: Other protocol-specified inclusion/exclusion criteria may apply.
What this study is about
In the sponsor’s own words, from the registry.
This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.
Study sites(61)
Neurocrine Clinical Site
Bryant, Arkansas, United States
Recruiting
Neurocrine Clinical Site
Little Rock, Arkansas, United States
Recruiting
Neurocrine Clinical Site
Cerritos, California, United States
Recruiting
Neurocrine Clinical Site
Chino, California, United States
Recruiting
Neurocrine Clinical Site
Culver City, California, United States
Recruiting
Neurocrine Clinical Site
Garden Grove, California, United States
Recruiting
Neurocrine Clinical Site
La Habra, California, United States
Recruiting
Neurocrine Clinical Site
Lemon Grove, California, United States
Recruiting
Neurocrine Clinical Site
Oceanside, California, United States
Recruiting
Neurocrine Clinical Site
Pico Rivera, California, United States
Recruiting
Neurocrine Clinical Site
Riverside, California, United States
Recruiting
Neurocrine Clinical Site
San Diego, California, United States
Recruiting
Neurocrine Clinical Site
Sherman, California, United States
Recruiting
Neurocrine Clinical Site
Torrance, California, United States
Recruiting
Neurocrine Clinical Site
West Hills, California, United States
Completed
Neurocrine Clinical Site
Atlantis, Florida, United States
Recruiting
Neurocrine Clinical Site
Aventura, Florida, United States
Recruiting
Neurocrine Clinical Site
Doral, Florida, United States
Withdrawn
Neurocrine Clinical Site
Hollywood, Florida, United States
Recruiting
Neurocrine Clinical Site
Maitland, Florida, United States
Recruiting
Neurocrine Clinical Site
Miami, Florida, United States
Recruiting
Neurocrine Clinical Site
Miami, Florida, United States
Withdrawn
Neurocrine Clinical Site
Miami Lakes, Florida, United States
Recruiting
Neurocrine Clinical Site
Tampa, Florida, United States
Recruiting
Neurocrine Clinical Site
West Palm Beach, Florida, United States
Recruiting
Neurocrine Clinical Site
Atlanta, Georgia, United States
Recruiting
Neurocrine Clinical Site
Atlanta, Georgia, United States
Recruiting
Neurocrine Clinical Site
Decatur, Georgia, United States
Recruiting
Neurocrine Clinical Sites
Peachtree Corners, Georgia, United States
Recruiting
Neurocrine Clinical Site
Chicago, Illinois, United States
Recruiting
Neurocrine Clinical Site
Oak Brook, Illinois, United States
Recruiting
Neurocrine Clinical Site
Gaithersburg, Maryland, United States
Recruiting
Neurocrine Clinical Site
Boston, Massachusetts, United States
Recruiting
Neurocrine Clinical Site
Watertown, Massachusetts, United States
Recruiting
Neurocrine Clinical Site
Flowood, Mississippi, United States
Recruiting
Neurocrine Clinical Site
St Louis, Missouri, United States
Recruiting
Neurocrine Clinical Site
Marlton, New Jersey, United States
Recruiting
Neurocrine Clinical Site
Cedarhurst, New York, United States
Recruiting
Neurocrine Clinical Site
New York, New York, United States
Recruiting
Neurocrine Clinical Site
New York, New York, United States
Recruiting
Neurocrine Clincial Site
Staten Island, New York, United States
Recruiting
Neurocrine Clinical Sites
The Bronx, New York, United States
Recruiting
Neurocrine Clinical Sites
North Canton, Ohio, United States
Recruiting
Neurocrine Clinical Site
Philadelphia, Pennsylvania, United States
Recruiting
Neurocrine Clinical Site
Austin, Texas, United States
Recruiting
Neurocrine Clinical Site
DeSoto, Texas, United States
Recruiting
Neurocrine Clinical Site
Houston, Texas, United States
Recruiting
Neurocrine Clinical Sites
Orem, Utah, United States
Recruiting
Neurocrine Clinical Site
Orem, Utah, United States
Recruiting
Neurocrine Clinical Site
Bellevue, Washington, United States
Recruiting
Neurocrine Clinical Site
Pleven, Bulgaria
Recruiting
Neurocrine Clinical Site
Veliko Tarnovo, Bulgaria
Withdrawn
Neurocrine Clinical Site
Vratsa, Bulgaria
Recruiting
Neurocrine Clinical Site
San Juan, Puerto Rico
Recruiting
Neurocrine Clinical Site
Brasov, Romania
Recruiting
Neurocrine Clinical Site
Bucharest, Romania
Completed
Neurocrine Clinical Site
Sânpetru, Romania
Recruiting
Neurocrine Clinical Site
Belgrade, Serbia
Recruiting
Neurocrine Clinical Site
Belgrade, Serbia
Withdrawn
Neurocrine Clinical Site
Gornja Toponica, Serbia
Recruiting
Showing 60 of 61 sites — filter to narrow it down. 55 of the 61 sites on this study are recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07114874. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me